BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11045266)

  • 1. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial.
    Ahsan N
    Adv Perit Dial; 2000; 16():80-4. PubMed ID: 11045266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ITDI is the preferred treatment for iron supplementation in rHuEpo-treated anemic PD patients.
    Ahsan N
    Adv Perit Dial; 1998; 14():228-31. PubMed ID: 10649730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis].
    Vanková S; Safárová R; Horácková M; Herink J; Rychlík I; Bahbouh R; Půtová I
    Cas Lek Cesk; 2001 Apr; 140(7):209-13. PubMed ID: 11374225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin.
    Mars RL; Moles K; Pope K; Hargrove P
    Adv Perit Dial; 1999; 15():60-4. PubMed ID: 10682073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
    Raja R; Bloom E; Johnson R; Goldstein M
    Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of bolus intravenous iron dextran treatment in peritoneal dialysis patients receiving recombinant human erythropoietin.
    Ahsan N; Groff JA; Waybill MA
    Adv Perit Dial; 1996; 12():161-6. PubMed ID: 8865893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study.
    Ahsan N
    J Am Soc Nephrol; 1998 Apr; 9(4):664-8. PubMed ID: 9555669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of iron saturation for erythropoietin responsiveness in chronic peritoneal dialysis.
    Jonnalagadda V; Bloom EJ; Raja RM
    Adv Perit Dial; 1997; 13():113-5. PubMed ID: 9360662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficiency of fractionated parenteral iron treatment in CAPD patients.
    Akcicek F; Ozkahya M; Cirit M; Ok E; Unsal A; Toz H; Celik A; Atabay G; Basci A
    Adv Perit Dial; 1997; 13():109-12. PubMed ID: 9360661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN.
    Johnson CA; Rosowski E; Zimmerman SW
    Adv Perit Dial; 1992; 8():444-7. PubMed ID: 1361844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin with oral iron in peritoneal and hemodialysis patients. A comparison in an inner city population.
    Raja R; Bloom E; Goldstein M; Johnson R
    ASAIO J; 1993; 39(3):M578-80. PubMed ID: 8268603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of intramuscular versus subcutaneous erythropoietin for the treatment of anemia in CAPD patients.
    Abreo K; Lubom JA; Collier L; Fleming D; Work J
    Adv Perit Dial; 1994; 10():124-8. PubMed ID: 7999809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with subcutaneous erythropoietin in CAPD patients.
    Bailie GR; Plitnick R; Eisele G; Clement C; Rasmussen R
    Adv Perit Dial; 1991; 7():292-5. PubMed ID: 1680449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis.
    Nakamoto H; Kanno Y; Okada H; Suzuki H
    Adv Perit Dial; 2004; 20():111-6. PubMed ID: 15384808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron dextran treatment in peritoneal dialysis patients on erythropoietin.
    Suh H; Wadhwa NK
    Adv Perit Dial; 1992; 8():464-6. PubMed ID: 1361849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.